By exploring new biomass sources and improving the preparation process or surface modification, B-CDs can be made to have anti-inflammatory, endothelialization-promoting, anticoagulation, and fluorescence imaging properties, which will play an important role in the application of vascular stents. Although B-CDs show extraordinary potential in the coating of vascular stents, there may be some challenges in practical applications, such as ensuring coating uniformity, long-term stability, and the feasibility of large-scale production. Future research may focus on improving B-CDs synthesis methods, synergies with drugs, optimizing coating processes, and exploring more functionalization strategies to fully realize the potential of B-CDs in vascular stents. At the same time, the long-term biosafety and biodegradability of B-CDs coating in vivo is also one of the future improvement directions. In addition, the study of B-CDs coatings also involves the combination of composites with other materials, such as metals or other nanoparticles, to create scaffolders with additional functions, such as promoting endothelialization or anti-inflammatory properties.

New research suggests that it disrupts biological clock. Exposure to light at night raises cardiovascular disease risk by up to 50 percent over sleeping in the dark, new research shows. But scientists say the effect isn’t from lack of sleep, but from disruption of the body’s master biological clock, the circadian rhythm.

At the American Heart Association Scientific Sessions, South Korean investigators reported the ADAPT AF-DES trial of anticoagulant monotherapy or combination therapy with a direct oral anticoagulant (DOAC) plus clopidogrel in patients with atrial fibrillation (AF) who had a drug-eluting stent at least 1 year earlier. This is very much a repeat of the AQUATIC trial, which showed clear superiority of anticoagulation monotherapy over anticoagulation plus low-dose aspirin in similar patients. 

The TUXEDO-2 study is a randomized clinical trial evaluating percutaneous coronary intervention strategies, including stent choice, revascularization approach, and antiplatelet therapy, in 1,800 adults in India with Type 1 or Type 2 diabetes and multivessel disease. All of the patients enrolled in the study had one of two specific drug-eluting stents implanted after a percutaneous coronary intervention to clear a blockage. Stents are implanted to increase blood flow in a narrowed or blocked vessel, and drug-eluting stents are coated with a medication to help reduce the risk of re-narrowing of the stents.

Nordanstig, who joined the session remotely, reiterated that drug-coated balloons and stents were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in the SWEDEPAD 1 and 2 trials of patients with chronic limb-threatening ischaemia (CLTI) and intermittent claudication, respectively. He added that higher five-year mortality with drug-coated devices in patients with intermittent claudication was noted. 

Drug-coated balloons and stents don’t reduce the risk of amputation or improve quality of life for people with peripheral artery disease in the legs. That’s the takeaway from two major clinical trials led by researchers at the University of Gothenburg.

Drug-eluting stents (DES) have largely overcome the major limitation of bare-metal stents (BMS) — namely, the high rate of vascular smooth muscle cell (VSMC)-driven in-stent restenosis — by releasing antiproliferative drugs that suppress excessive neointimal hyperplasia. However, late and very late stent thromboses have emerged as new challenges of DES, caused not by mechanical complications or VSMC proliferation, but by a rapid, lipid-driven atherosclerotic process within stented segments, termed in-stent neoatherosclerosis.

The SUGAR trial demonstrates that AES and O-ZES provide comparable long-term efficacy in preventing TLF in patients with DM undergoing PCI. These findings support the use of either stent type and highlight the importance of further long-term studies to optimise outcomes.

The results show that patients with type 1 diabetes have more than twice the risk of stent complications compared to patients without diabetes. For patients with type 2 diabetes, the risk is also elevated, but not as significantly. Complications include both narrowing of the artery in the stent and blood clots in the stent.

Around 1 in 5 patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) experienced target lesion failure (TLF) within 10 years, with older age and other comorbidities identified as risk factors.

Coronary Artery Disease (CAD) remains a leading cause of death globally, but the treatments are rapidly changing. While traditional methods like lifestyle changes, medications, and surgeries have long been the cornerstone of care, these are now being enhanced by modern innovations. As highlighted by Nishi Patel, recent medical therapies target underlying biological processes, offering new hope to patients previously considered high-risk or untreatable.

Sometimes, a feeling of chest discomfort, shortness of breath, or loss of energy may be more than stress or fatigue. To many individuals, the symptoms indicate that the heart may be having difficulties in pumping sufficient blood to the body. Implanting a stent, which is a small and lifesaving gadget that keeps arteries open, is one of the most widespread measures taken in such instances. But knowing when a stent is needed is not as simple as assuming that every chest pain requires one. That is the decision that doctors give after a thorough consideration of the symptoms, results of tests done, and the general health of the heart.

As the use of Drug Coated Balloons has gained traction over time, limitations of the technology have become apparent, including a reported 2–4% annual adverse event rate at long-term follow-up. This has given rise to a need for new strategies to minimise stenting or leave no permanent implant behind following a PCI procedure. DCB technologies offer promise in overcoming these limitations, facilitating the delivery of potent antiproliferative drugs without the need for a permanent scaffold. However, whilst there have been promising data in select subsets, DCBs have yet to excel in studies involving de novo coronary artery disease.

Antiplatelet therapy is the cornerstone of treatment in patients with established atherosclerotic disease. The use of a single antiplatelet agent is commonly recommended for the long-term management of these patients. Although aspirin has represented the mainstay of antiplatelet therapy for decades, emerging evidence suggests that P2Y₁₂ inhibitors may be more than just a viable alternative to aspirin and may be preferred over aspirin. This review examines the current evidence comparing the efficacy and safety of aspirin vs P2Y12 inhibitors in reducing cardiovascular events in patients with atherosclerotic disease.

Anti-OxLDL CAR Tregs mitigate inflammation and plaque deposition associated with oxidized LDL and may offer a new therapeutic option for atherosclerosis.

This study reveals clinically significant differences in CAD patterns between sexes, with women demonstrating a higher burden of angina, more focal disease distribution, and better physiological results after PCI.

Le cathétérisme cardiaque (CC) et les examens électrophysiologiques (EP) sont des éléments fondamentaux du diagnostic et de l'intervention cardiovasculaires modernes. Bien que ces deux procédures impliquent un accès mini-invasif au cœur par voie vasculaire périphérique sous contrôle fluoroscopique, elles ont des objectifs distincts : le CC évalue principalement l'intégrité structurelle, les pressions et le débit sanguin (hémodynamique) du cœur et des artères coronaires, tandis que les examens EP sont spécialisés dans la cartographie et l'évaluation du système de conduction électrique.

This case highlights the need for heightened vigilance and awareness of the potential arterial thrombosis risk associated with oral contraceptive pill use, especially in young women with no other cardiovascular risk factors.

L’étude a été arrêtée prématurément le 16 avril 2024 sur recommandation du comité de surveillance en raison d’un excès de mortalité globale dans un groupe. La durée médiane de traitement était de 1,7 an (IQR 0,7-2,8) et le suivi médian de 2,2 ans (IQR 1,1-3,2).

Mit PolyMediX® hat MeKo ein innovatives Herstellungsverfahren entwickelt, das Polymerrohre auf höchstem Qualitätsniveau ermöglicht. Unser Verfahren kombiniert Präzision, Gestaltungsfreiheit und Integrität – und schafft damit eine solide Grundlage für die Medizintechnik von morgen. Dank der engen Verzahnung mit unserer Fertigung entstehen aus wenigen Gramm Material in kürzester Zeit Prototypen und Kleinserien, die sich in Forschung und klinischer Anwendung bewähren.